Ganoderic acid A exerts antitumor activity against MDA‑MB‑231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway-Reference-Cited by-同舟云学术

Ganoderic acid A exerts antitumor activity against MDA‑MB‑231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway

Published:2018-09-21 Issue: Volume: Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Yang Yuguang¹,Zhou Hongfeng¹,Liu Wenming¹,Wu Jin¹,Yue Xiaolong¹,Wang Jincai¹,Quan Lina¹,Liu Hang¹,Guo Li¹,Wang Zhipeng²,Lian Xin³,Zhang Qingyuan¹

Affiliation:

1. Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China

2. Department of Medical Oncology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China

3. Department of Medical Oncology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization;Phytomedicine;2024-07

2. Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer;Frontiers in Oncology;2024-04-18

3. Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer;European Journal of Medicinal Chemistry;2024-04

4. Ganoderic acid A suppresses autophagy by regulating the circFLNA/miR-486-3p/CYP1A1/XRCC1 axis to strengthen the sensitivity of lung cancer cells to cisplatin;Journal of Pharmacy and Pharmacology;2024-02-08

5. Design, synthesis, and biological evaluation of novel 4,4′-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer;European Journal of Medicinal Chemistry;2023-12